Introduction {#sec1}
============

Cross-dehydrogenative coupling (CDC) that combines two C--H bonds to form a new carbon--carbon (C--C) bond has attracted much attention of organic chemists in the past decade.^[@ref1]−[@ref6]^ Traditional cross-coupling reactions utilize prefunctionalized starting precursors as organohalides and/or organometallic derivatives. They lead to stoichiometric amounts of waste, whereas couplings via CDC of C(sp^2^)--H bonds are economical and powerful tools to synthesize complex heterocycles.^[@ref7]^ These methods have been studied by employing various metal catalysts, organocatalysts, and photocatalysts to synthesize a wide range of organic molecules. In quest of other efficient and green organic transformations, direct functionalization of C--H bonds with metal catalyst plays a vital role in all areas of chemistry.^[@ref8]−[@ref12]^ Among them, palladium-catalyzed CDC reactions have appeared as one of the most significant new approaches in organic synthesis.^[@ref13]−[@ref23]^ A few protocols have been reported with palladium to access fused heterocycles via an intramolecular CDC.^[@ref7],[@ref24]^

The use of direct oxidative intramolecular CDC for imine and enamine compounds for the construction of fused heterocycles is of interest. The reported CDC reactions contained a stoichiometric amount of oxidants, such as PhI(OAc)~2~,^[@ref25]^ MnO~2~,^[@ref26]^ TBHP,^[@ref27]^ Cu(OAc)~2~,^[@ref28]−[@ref31]^ AgOAc,^[@ref32]^ and others,^[@ref33],[@ref34]^ to maintain the catalytic cycle, which produced large amounts of waste and toxic byproducts. An elegant approach to avoid these limitations was the use of oxygen as a sole oxidant, which produced water as by-product after the reaction.^[@ref25]^

The heteroaryl scaffold containing imidazo\[1,2-*a*\]pyrimidine is a masked form of the 2-aminoimidazole moiety, which showed prominent biological applications ([Figure [1](#fig1){ref-type="fig"}](#fig1){ref-type="fig"}) as anxiolytic (A),^[@ref35]^ p38 kinase inhibitor (B),^[@ref36]^ anticonvulsant (C),^[@ref37]^ DPP4 inhibitor (D),^[@ref38]^ and androgen receptor antagonist (E).^[@ref39]^ The synthesis of imidazo\[1,2-*a*\]pyrimidines has been previously reported from nitrenoids in the presence of gold catalysts ([Scheme [1](#sch1){ref-type="scheme"}](#sch1){ref-type="scheme"}a)^[@ref40]^ and from pyrimidyl arylamines or enamines with hypervalent iodine reagent ([Scheme [1](#sch1){ref-type="scheme"}](#sch1){ref-type="scheme"}b).^[@ref41]^ Some of the reported methods need longer reaction times, require starting materials, which are synthesized in multiple steps, and have limited substrate scope. Thus, it is necessary to develop a simple and safer alternative method for these compounds. Herein, we report our initial results on the synthesis of imidazo\[1,2-*a*\]pyrimidines via a tandem reaction of amine and aldehyde derivatives under palladium catalysis, which involves oxidative CDC in the presence of air as an oxidant ([Scheme [1](#sch1){ref-type="scheme"}](#sch1){ref-type="scheme"}c). To the best of our knowledge, this is the first report of using CDC reaction to produce fused imidazo\[1,2-*a*\]pyrimidine analogues.

![Biologically potent imidazo\[1,2-*a*\]pyrimidines.](ao-2016-00417g_0001){#fig1}

![Various Pathways to Synthesize Imidazo\[1,2-*a*\]pyrimidine](ao-2016-00417g_0002){#sch1}

Results and Discussion {#sec2}
======================

Our initial experiment commenced with the reaction of 1*H*-benzo\[*d*\]imidazol-2-amine (**1a**) and 2-phenylacetaldehyde (**2a**) in the presence of CuCl~2~ and K~2~CO~3~ in toluene at 80 °C for 4 h, which resulted in the desired product, phenyl(3-phenylbenzo\[4,5\]imidazo\[1,2-*a*\]pyrimidin-2-yl)methanone (**3a**), with a yield of less than 10% ([Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"}, entry 1). Other halogenated metal salts, such as Fe, Pd, Zn, and Sn, were scrutinized to increase the yield of **3a** (entries 2--6), and among them, PdCl~2~ showed better results by giving 80% yield of **3a** (entry 4, [Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"}). Next, we focused on screening different palladium salts, such as Pd(OAc)~2~, Pd(OH)~2~, and Pd(TFA)~2~ (entries 7--9), to improve the yield of **3a** further and found that PdCl~2~ was the best among all of these palladium catalysts. After choosing PdCl~2~, various bases were also screened (entries 10--12), among which K~2~CO~3~ (entry 4) was found to give a higher yield of **3a**. The evaluation of reaction solvents, such as acetonitrile, dimethylformamide (DMF), dimethyl sulfoxide (DMSO), and tetrahydrofuran (THF) (entries 13--16), revealed that toluene is the preferred solvent for this reaction. The reaction temperature and the amount of the reagent were also optimized (entries 17--20). The reaction of 1*H*-benzo\[*d*\]imidazol-2-amine **1a** and 2-phenylacetaldehyde **2a** (2 mmol) in the presence of PdCl~2~ and K~2~CO~3~ in toluene at room temperature did not produce **3a** (entry 17). The yield of **3a** was not high at elevated temperature (entry 18). Importantly, lowering of the PdCl~2~ to 2 mol % or increasing to 10 mol % had no impact on the reaction rate (entries 19 and 20, respectively). The reaction time was increased from 4 to 6 h, with no change in the yield (entry 21). Among all of these reaction conditions, the optimized condition was chosen as entry 4 in [Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"}. The structure of **3a** was confirmed by X-ray crystallographic analysis ([Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"}; files [si_001](http://pubs.acs.org/doi/suppl/10.1021/acsomega.6b00417/suppl_file/ao6b00417_si_001.cif) and [si_002](http://pubs.acs.org/doi/suppl/10.1021/acsomega.6b00417/suppl_file/ao6b00417_si_002.cif) of the Supporting Information).^[@ref42]^

###### Optimization of Reaction Conditions for the Synthesis of Imidazo\[1,2-*a*\]pyrimidines[a](#t1fn1){ref-type="table-fn"}

![](ao-2016-00417g_0005){#fx1}

  entry                                catalyst     base         temp (°C)   solvent   yield (%)
  ------------------------------------ ------------ ------------ ----------- --------- -----------
  1                                    CuCl~2~      K~2~CO~3~    80          PhMe      \<10
  2                                    FeCl~2~      K~2~CO~3~    80          PhMe      \<10
  3                                    FeCl~3~      K~2~CO~3~    80          PhMe      \<10
  4                                    PdCl~2~      K~2~CO~3~    80          PhMe      80
  5                                    ZnCl~2~      K~2~CO~3~    80          PhMe      30
  6                                    SnCl~2~      K~2~CO~3~    80          PhMe      26
  7                                    Pd(OAc)~2~   K~2~CO~3~    80          PhMe      47
  8                                    Pd(OH)~2~    K~2~CO~3~    80          PhMe      34
  9                                    Pd(TFA)~2~   K~2~CO~3~    80          PhMe      39
  10                                   PdCl~2~      Na~2~CO~3~   80          PhMe      64
  11                                   PdCl~2~      Cs~2~CO~3~   80          PhMe      71
  12                                   PdCl~2~      Li~2~CO~3~   80          PhMe      69
  13                                   PdCl~2~      K~2~CO~3~    80          CH~3~CN   63
  14                                   PdCl~2~      K~2~CO~3~    80          DMF       58
  15                                   PdCl~2~      K~2~CO~3~    80          DMSO      61
  16                                   PdCl~2~      K~2~CO~3~    80          THF       43
  17                                   PdCl~2~      K~2~CO~3~    28          PhMe      0
  18                                   PdCl~2~      K~2~CO~3~    100         PhMe      76
  19[b](#t1fn2){ref-type="table-fn"}   PdCl~2~      K~2~CO~3~    80          PhMe      78
  20[c](#t1fn3){ref-type="table-fn"}   PdCl~2~      K~2~CO~3~    80          PhMe      80
  21[d](#t1fn4){ref-type="table-fn"}   PdCl~2~      K~2~CO~3~    80          PhMe      80
  22                                   PdCl~2~      K~2~CO~3~    60          PhMe      62
  23[e](#t1fn5){ref-type="table-fn"}   PdCl~2~      K~2~CO~3~    80          PhMe      78

**1a** (1 mmol), **2a** (2 mmol), catalyst (5 mol %), base (2 mmol), 80 °C, 4 h.

PdCl~2~ (2 mol %).

PdCl~2~ (10 mol %).

6 h.

PdCl~2~ (3 mol %).

To examine the scope of the developed protocol, a series of imidazo\[1,2-*a*\]pyrimidine derivatives was synthesized by the reaction of differently substituted 1*H*-benzo\[*d*\]imidazol-2-amines **1** and 2-arylacetaldehyde **2**. The results are summarized in [Table [2](#tbl2){ref-type="other"}](#tbl2){ref-type="other"}. The starting materials containing electron-donating groups gave higher yields (**3b**--**f**, **3h**, and **3m**--**p**) compared to those of materials containing electron-withdrawing groups (**3g**, **3i**, and **3j**--**l**). The reaction with a strong electron-withdrawing group, −NO~2~ (**3q**), was detected in the crude reaction mixture using mass spectrometry; however, the isolation was not successful due to the stability of the compound. An aliphatic aldehyde was used instead of 2-phenylacetaldehyde for the reaction, which provided none of the desired compound (**3r**); our assumption was that the low stability of enamine may be the reason of failure.

###### Synthesis of Imidazo\[1,2-*a*\]pyrimidines by CDC[a](#t2fn1){ref-type="table-fn"}^,^[b](#t2fn2){ref-type="table-fn"}

![](ao-2016-00417g_0006){#fx2}

Compound **1a** (1 mmol), compound **2a** (2 mmol), catalyst (5 mol %), base (2 mmol), 80 °C, 4 h.

High resolution mass spectra (HRMS) showed peak of comp **3q**.

To explore the applicability of the developed reaction further, we tested single-ring heterocycles, such as 1*H*-pyrazol-5-amine and 1*H*-imidazol-2-amine, as starting materials. The reaction succeeded and resulted in satisfactory yields of the corresponding fused heterocycles **5a**--**f** ([Table [3](#tbl3){ref-type="other"}](#tbl3){ref-type="other"}). The formation of these products in good to excellent yields suggests the generality of the developed method.

###### Direct Way to Synthesize Fused Bicyclic Systems[a](#t3fn1){ref-type="table-fn"}

![](ao-2016-00417g_0007){#fx3}

Compound **4a** (1 mmol), **2a** (2 mmol), catalyst (5 mol %), base (2 mmol), 80 °C, 4 h.

We performed functional group transformation of compound **3a** ([Scheme [2](#sch2){ref-type="scheme"}](#sch2){ref-type="scheme"}) through reduction with NaBH~4~ to produce alcohol **6a**. An attempt to synthesize the hydrazone derivative of compound **3a** resulted in the formation of compound **7**, which was confirmed by HRMS.

![Applications of Compound **3a**](ao-2016-00417g_0003){#sch2}

A plausible mechanism is proposed in [Scheme [3](#sch3){ref-type="scheme"}](#sch3){ref-type="scheme"} for the synthesis of imidazo\[1,2-*a*\]pyrimidine derivatives. In the proposed mechanism, the initial step involves the formation of intermediate **A** by the condensation of **4a** with **2a**, which then reacts with Pd(II) to generate intermediate **B**. The deprotonation of intermediate **B** leads to vinyl Pd intermediate **C**, which undergoes an intramolecular attack with imine to give seven-membered palladium cycle **D**. The 1,2-Pd migration in intermediate **D** produces six-membered aza cyclic compound **E**, which may result in the formation of intermediate **F** or **F′** after reductive palladium elimination. Intermediate **F′** could undergo a well-known Wacker--Tsuji type of oxidation in the presence of Pd (II). Pd(O) was oxidized by utilizing the oxygen to produce Pd(II), which further could lead to a π complex species in compound **G**. This compound is expected to undergo hydration in the presence of water, which may lead to compound **I**, and it could undergo reductive elimination of Pd to yield compound **J** that is finally oxidized to give the desired product, **5a**.

![Plausible Mechanism to Synthesize Imidazo\[1,2-*a*\]pyrimidine Derivatives](ao-2016-00417g_0004){#sch3}

Conclusions {#sec3}
===========

In conclusion, we have developed a simple, mild, and efficient method for the synthesis of fused imidazo\[1,2-*a*\]pyrimidines and pyrazolo\[1,5-*a*\]pyrimidines via a tandem reaction of the corresponding 2-arylacetaldehyde and azole-amine in the presence of PdCl~2~. The developed protocol will be not only applicable as a versatile method for the mentioned heterocycles but also useful to construct complex derivatives.

Experimental Section {#sec4}
====================

General Information {#sec4.1}
-------------------

Unless otherwise noted, all of the reactions for the preparation of the substrates were performed in oven-dried glassware with freshly distilled solvents. The solvents were dried under standard methods. All other commercial reagents were used without further purification. ^1^H NMR and ^13^C NMR spectra were recorded on Bruker 400 MHz spectrometers using chloroform-d (CDCl~3~) as the internal standard. Multiplicities were denoted as (s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet or overlap of nonequivalent resonances, integration). Aluminum-backed plates precoated with silica gel 60F254 were used for thin-layer chromatography and were visualized with a UV lamp. The melting points were uncorrected. MS and HRMS were obtained on QTOF Bruker Impact II using electrospray ionization (ESI) source. X-ray was recorded on Bruker D8 venture gallium liquid metal jet single-crystal diffraction system. Flash column chromatography was carried out over silica gel 60 (230--400 mesh).

Experimental Procedures and Spectral Data {#sec4.2}
-----------------------------------------

### General Procedure for the Synthesis of Fused Imidazo\[1,2-*a*\]pyrimidines {#sec4.2.1}

A suspension of *1H*-benzo\[*d*\]imidazol-2-amine **1** (100 mg, 1.00 mmol, 1.00 equiv), 2-phenylacetaldehyde **2** (180.4 mg, 2 equiv), PdCl~2~ (6.65 mg, 0.037 mmol, 5 mol%), and K~2~CO~3~ (101 mg, 2.00 equiv) in anhydrous toluene (5.0 mL) was stirred at 80 °C for 4 h under oxygen atmosphere (1 atm). At ambient temperature, the solvent was evaporated in vacuo and the remaining residue was purified by column chromatography on silica gel (*n*-hexane/EtOAc) to yield product **3a**. Similar procedures were followed to synthesize compounds **3b**--**p** and **5a**--**e**([Supporting Information](http://pubs.acs.org/doi/suppl/10.1021/acsomega.6b00417/suppl_file/ao6b00417_si_003.pdf)).

#### Phenyl(3-phenylbenzo\[4,5\]imidazo\[1,2-*a*\]pyrimidin-2-yl)methanone (**3a**) {#sec4.2.1.1}

This compound was obtained as a yellow solid (80%) with mp 204.4--206.4 °C; ^1^H NMR (400 MHz, CDCl~3~): δ 8.81 (s, 1H), 8.00--7.91 (m, 4H), 7.60--7.56 (m, 2H), 7.44--7.41 (m, 3H), 7.31 (s, 5H); ^13^C NMR (100 MHz, CDCl~3~): δ 192.0, 160.7, 148.4, 145.2, 135.0, 134.2, 133.5, 133.2, 130.6, 129.0, 128.9, 128.7, 128.5, 127.1, 122.8, 120.8, 111.1; HRMS (ESI) calcd \[C~23~H~16~N~3~O\] \[M + H\]^+^: 350.1294, found: 350.1291.

#### (4-Methoxyphenyl)(3-(4-methoxyphenyl)benzo\[4,5\]imidazo\[1,2-*a*\]pyrimidin-2-yl)methanone (**3b**) {#sec4.2.1.2}

This compound was obtained as a yellow solid (72%) with mp 190.7--192.3 °C; ^1^H NMR (400 MHz, CDCl~3~): δ 8.73 (s, 1H), 7.97--7.89 (m, 4H), 7.57 (s, 1H), 7.42 (s, 1H), 7.24--7.23 (m, 2H), 6.90--6.83 (m, 4H), 3.85 (s, 3H), 3.76 (s, 3H); ^13^C NMR (100 MHz, CDCl~3~): δ 190.8, 164.5, 161.4, 159.9, 148.4, 145.1, 133.1, 132.8, 130.3, 128.3, 126.8, 125.9, 122.7, 120.8, 114.4, 114.0, 110.0, 55.6, 55.3; HRMS (ESI) calcd \[C~25~H~20~N~3~O~3~\] \[M + H\]^+^: 410.1505, found: 410.1500.

#### (3-Methoxyphenyl)(3-(3-methoxyphenyl)benzo\[4,5\]imidazo\[1,2-*a*\]pyrimidin-2-yl)methanone (**3c**) {#sec4.2.1.3}

This compound was obtained as a yellow solid (70%) with mp 202.3--204.1 °C; ^1^H NMR (400 MHz, CDCl~3~): δ 8.87 (s, 1H), 8.10 (s, 1H), 8.00--7.99 (m, 1H), 7.64 (s, 1H), 7.56--7.48 (m 3H), 7.36 (t, *J* = 8.0 Hz, 1H), 7.30--7.26 (m, 1H), 7.16 (d, *J* = 8.0 Hz, 1H), 6.94--6.89 (m, 3H), 3.83 (s, 3H), 3.71 (s, 3H); ^13^C NMR (100 MHz, CDCl~3~): δ 191.8, 160.8, 159.8, 136.4, 134.8, 132.9, 130.1, 129.7, 127.1, 124.0, 122.9, 121.3, 121.2, 120.9, 114.6, 114.3, 113.7, 110.9, 55.5, 55.2; HRMS (ESI) calcd \[C~25~H~20~N~3~O~3~\] \[M + H\]^+^: 410.1505, found: 410.1502.

#### (7,8-Dimethyl-3-phenylbenzo\[4,5\]imidazo\[1,2-*a*\]pyrimidin-2-yl)(phenyl)methanone (**3d**) {#sec4.2.1.4}

This compound was obtained as a yellow solid (71%) with mp 118.5--120.2 °C; ^1^H NMR (400 MHz, CDCl~3~): δ 8.83 (s, 1H), 7.99 (s, 2H), 7.85--7.77 (m, 2H), 7.56--7.28 (m, 8H), 2.44 (s, 6H); ^13^C NMR (100 MHz, CDCl~3~): δ 192.2, 171.2, 159.0, 136.9, 135.2, 134.0, 133.8, 133.1, 132.8, 130.6, 128.9, 128.8, 128.6, 128.3, 120.7, 111.1, 20.8, 20.7; HRMS (ESI) calcd \[C~25~H~20~N~3~O\] \[M + H\]^+^: 378.1607, found: 378.1605.

#### (7,8-Dimethyl-3-(*p*-tolyl)benzo\[4,5\]imidazo\[1,2-*a*\]pyrimidin-2-yl)(*p*-tolyl)methanone (**3e**) {#sec4.2.1.5}

This compound was obtained as a yellow solid (74%) with mp 114.7--116.4 °C; ^1^H NMR (400 MHz, CDCl~3~): δ 8.75 (s, 1H), 7.92 (d, *J* = 8 Hz, 2H), 7.83 (s, 1H), 7.74 (s, 1H), 7.26--7.21 (m, 4H), 7.14 (d, *J* = 8 Hz, 2H), 2.49 (s, 3H), 2.48 (s, 3H), 2.42 (s, 3H), 2.33 (s, 3H); ^13^C NMR (100 MHz, CDCl~3~): δ 191.9, 159.7, 145.2, 138.4, 136.8, 132.8, 132.6, 132.5, 131.0, 130.8, 129.7, 129.4, 128.7, 120.7, 110.8, 21.9, 21.2, 20.9, 20.8; HRMS (ESI) calcd \[C~27~H~24~N~3~O\] \[M + H\]^+^: 406.1920, found: 406.1914.

#### (4-Methoxyphenyl)(3-(4-methoxyphenyl)-7,8-dimethylbenzo\[4,5\]imidazo\[1,2-*a*\]pyrimidin-2-yl)methanone (**3f**) {#sec4.2.1.6}

This compound was obtained as a yellow solid (70%) with mp 226.6--228.3 °C; ^1^H NMR (400 MHz, CDCl~3~): δ 8.69 (s, 1H), 7.97 (d, *J* = 8 Hz, 2H), 7.77--7.70 (m, 2H), 7.23 (d, *J* = 8 Hz, 2H), 6.86 (dd, *J* = 8, 20 Hz, 4H), 3.86 (s, 3H), 3.76 (s, 3H), 2.47 (s, 3H), 2.45 (s, 3H); ^13^C NMR (100 MHz, CDCl~3~): δ 191.0, 164.4, 159.7, 133.1, 132.5, 130.1, 128.3, 126.1, 120.4, 114.3, 114.0, 110.8, 55.6, 55.3, 20.9, 20.8; HRMS (ESI) calcd \[C~27~H~24~N~3~O~3~\] \[M + H\]^+^: 438.1818, found: 438.1809.

#### (4-Chlorophenyl)(3-(4-chlorophenyl)-7,8-dimethylbenzo\[4,5\]imidazo\[1,2-*a*\]pyrimidin-2-yl)methanone (**3g**) {#sec4.2.1.7}

This compound was obtained as a yellow solid (62%) with mp 149.6--151.4 °C; ^1^H NMR (400 MHz, CDCl~3~): δ 8.89 (s, 1H), 8.00 (s, 2H), 7.51 (s, 1H), 7.41 (s, 2H), 7.32 (d, *J* = 8 Hz, 2H), 7.26--7.23 (m, 3H), 2.49 (s, 3H), 2.46 (s, 3H); ^13^C NMR (100 MHz, CDCl~3~): δ 190.7, 157.8, 141.0, 137.2, 137.0, 134.8, 133.4, 133.3, 132.3, 132.0, 130.1, 129.2, 129.1, 119.7, 111.2, 20.9, 20.8; HRMS (ESI) calcd \[C~25~H~18~Cl~2~N~3~O\] \[M + H\]^+^: 446.0828, found: 446.0831.

#### (3-Methoxyphenyl)(3-(3-methoxyphenyl)-7,8-dimethylbenzo\[4,5\]imidazo\[1,2-*a*\]pyrimidin-2-yl)methanone (**3h**) {#sec4.2.1.8}

This compound was obtained as a yellow solid (77%) with mp 166.8--168.2 °C; ^1^H NMR (400 MHz, CDCl~3~): δ 8.75 (s, 1H), 7.78 (s, 1H), 7.69 (s, 1H), 7.57--7.53 (m, 2H), 7.33 (t, *J* = 8.0 Hz, 1H), 7.22 (t, *J* = 8.0 Hz, 1H); 7.15--7.12 (m, 1H), 6.88--6.82 (m, 3H), 3.81 (s, 3H), 3.67 (s, 3H), 2.47 (s, 6H); ^13^C NMR (100 MHz, CDCl~3~): δ 192.0, 159.79, 159.77, 159.5, 148.0, 144.1, 136.9, 136.5, 135.1, 132.7, 132.6, 130.0, 129.6, 125.3, 124.0, 121.2, 121.0, 120.7, 120.5, 114.5, 114.0, 113.7, 110.8, 55.5, 55.2, 20.9, 20.8; HRMS (ESI) calcd \[C~27~H~24~N~3~O~3~\] \[M + H\]^+^: 438.1818, found: 438.1815.

#### (7,8-Dichloro-3-phenylbenzo\[4,5\]imidazo\[1,2-*a*\]pyrimidin-2-yl)(phenyl)methanone (**3i**) {#sec4.2.1.9}

This compound was obtained as a yellow solid (64%) with mp 113.2--115.1 °C; ^1^H NMR (400 MHz, CDCl~3~): δ 8.83 (s, 1H), 8.14--7.96 (m, 3H), 7.61--7.26 (m, 9H); ^13^C NMR (100 MHz, CDCl~3~): δ 191.7, 171.6, 161.8, 144.5, 134.5, 132.9, 130.55, 130.51, 129.1, 128.8, 128.7, 127.0, 122.1, 112.77, 112.74; HRMS (ESI) calcd \[C~23~H~14~Cl~2~N~3~O\] \[M + H\]^+^: 418.0515, found: 418.0502.

#### (7,8-Dichloro-3-(*p*-tolyl)benzo\[4,5\]imidazo\[1,2-*a*\]pyrimidin-2-yl)(*p*-tolyl)methanone (**3j**) {#sec4.2.1.10}

This compound was obtained as a pale brown solid (68%) with mp 267.7--269.3 °C; ^1^H NMR (400 MHz, CDCl~3~): δ 8.78 (s, 1H), 8.17--8.12 (m, 2H), 7.88--7.86 (m, 2H); 7.26--7.12 (m, 6H), 2.42 (s, 3H), 2.31 (s, 3H); ^13^C NMR (100 MHz, CDCl~3~): δ 191.3, 162.2, 145.7, 138.9, 132.8, 132.3, 131.4, 130.7, 130.0, 129.8, 129.5, 128.6, 126.8, 122.1, 112.6, 21.9, 21.2; HRMS (ESI) calcd \[C~25~H~18~Cl~2~N~3~O\] \[M + H\]^+^: 446.0828, found: 446.0833.

#### (7,8-Dichloro-3-(4-methoxyphenyl)benzo\[4,5\]imidazo\[1,2-*a*\]pyrimidin-2-yl)(4-methoxyphenyl)methanone (**3k**) {#sec4.2.1.11}

This compound was obtained as a pale brown solid (66%) with mp 210.5--212.2 °C; ^1^H NMR (400 MHz, CDCl~3~): δ 8.74 (s, 1H), 8.08 (s, 2H); 7.91 (d, *J* = 8 Hz, 2H), 7.18 (d, *J* = 8 Hz, 2H), 6.89 (d, *J* = 8 Hz, 2H), 6.78 (d, *J* = 8 Hz, 2H), 3.87 (s, 3H), 3.73 (s, 3H); ^13^C NMR (100 MHz, CDCl~3~): δ 190.4, 164.6, 162.5, 159.9, 132.9, 132.7, 131.2, 130.0, 127.7, 126.6, 125.1, 121.8, 121.6, 114.4, 114.1, 112.7, 55.6, 55.2; HRMS (ESI) calcd \[C~25~H~18~Cl~2~N~3~O~3~\] \[M + H\]^+^: 478.0726, found: 478.0719.

#### (4-Chlorophenyl)(7,8-dichloro-3-(4-chlorophenyl)benzo\[4,5\]imidazo\[1,2-*a*\]pyrimidin-2-yl)methanone (**3l**) {#sec4.2.1.12}

This compound was obtained as a pale brown solid (42%) with mp 221.5--223.3 °C; ^1^H NMR (400 MHz, CDCl~3~): δ 8.80 (s, 1H), 8.10--7.93 (m, 4H); 7.42--7.23 (m, 6H); ^13^C NMR (100 MHz, CDCl~3~): δ 190.1, 160.6, 141.4, 135.4, 133.4, 132.8, 131.9, 131.3, 130.1, 129.4, 129.3, 127.5, 122.0, 121.0, 112.7; HRMS (ESI) calcd \[C~23~H~12~Cl~4~N~3~O\] \[M + H\]^+^: 485.9735, found: 485.9738.

#### (7,8-Dimethoxy-3-phenylbenzo\[4,5\]imidazo\[1,2-*a*\]pyrimidin-2-yl)(phenyl)methanone (**3m**) {#sec4.2.1.13}

This compound was obtained as an orange solid (78%) with mp 196.7--198.3 °C; ^1^H NMR (400 MHz, CDCl~3~): δ 8.71 (s, 1H), 8.02 (d, *J* = 8.0 Hz, 2H), 7.59 (t, *J* = 8.0 Hz, 1H); 7.46--7.42 (m, 4H), 7.35--7.31 (m, 5H), 4.02 (s, 3H), 4.02 (s, 3H); ^13^C NMR (100 MHz, CDCl~3~): δ 192.2, 157.1, 150.8, 147.9, 140.6, 135.4, 134.1, 134.0, 131.6, 130.7, 128.9, 128.6, 128.4, 121.1, 101.4, 92.5, 56.5, 56.4; HRMS (ESI) calcd \[C~25~H~20~N~3~O~3~\] \[M + H\]^+^: 410.1505, found: 410.1493.

#### (7,8-Dimethoxy-3-(4-methoxyphenyl)benzo\[4,5\]imidazo\[1,2-*a*\]pyrimidin-2-yl)(4-methoxyphenyl)methanone (**3n**) {#sec4.2.1.14}

This compound was obtained as a brown solid (73%) with mp 147.8--149.6 °C; ^1^H NMR (400 MHz, CDCl~3~): δ 8.86 (s, 1H), 7.87 (d, *J* = 8.0 Hz, 2H), 7.44--7.43 (m, 2H), 7.19 (d, *J* = 8.0 Hz, 2H), 6.83 (d, *J* = 8.0 Hz, 2H), 6.74 (d, *J* = 8.0 Hz, 2H), 3.97 (s, 3H), 3.92 (s, 3H), 3.83 (s, 3H), 3.69 (s, 3H); ^13^C NMR (100 MHz, CDCl~3~): δ 190.9, 164.5, 159.7, 158.8, 151.1, 148.0, 146.5, 132.9, 132.1, 130.0, 127.9, 125.5, 121.5, 119.7, 114.3, 114.0, 100.1, 93.2, 56.6, 56.3, 55.6, 55.2; HRMS (ESI) calcd \[C~27~H~24~N~3~O~5~\] \[M + H\]^+^: 470.1717, found: 470.1704.

#### (7,8-Dimethoxy-3-(3-methoxyphenyl)benzo\[4,5\]imidazo\[1,2-*a*\]pyrimidin-2-yl)(3-methoxyphenyl)methanone (**3o**) {#sec4.2.1.15}

This compound was obtained as a yellow solid (70%) with mp 191.9--193.2 °C; ^1^H NMR (400 MHz, CDCl~3~): δ 8.81 (s, 1H), 7.53 (br, 2H), 7.39--7.33 (m, 2H), 7.27 (s, 1H), 7.23 (t, *J* = 4.0 Hz, 1H), 7.14 (d, *J* = 8.0 Hz, 1H), 6.91--6.83 (m, 3H), 4.02 (s, 3H), 3.82 (s, 3H), 3.68 (s, 3H); ^13^C NMR (100 MHz, CDCl~3~): δ 192.2, 159.8, 159.7, 157.1, 136.6, 135.3, 131.7, 130.0, 129.6, 124.0, 121.3, 120.1, 120.8, 114.6, 113.9, 113.8, 92.6, 56.5, 56.4, 55.5, 55.2; HRMS (ESI) calcd \[C~27~H~24~N~3~O~5~\] \[M + H\]^+^: 470.1717, found: 470.1711.

#### (7,8-Dimethoxy-3-(*p*-tolyl)benzo\[4,5\]imidazo\[1,2-*a*\]pyrimidin-2-yl)(*p*-tolyl)methanone (**3p**) {#sec4.2.1.16}

This compound was obtained as a yellow solid (74%) with mp 232.2--234.1 °C; ^1^H NMR (400 MHz, CDCl~3~): δ 8.67 (s, 1H), 7.97 (d, *J* = 8.0 Hz, 2H), 7.76--7.69 (m, 2H), 7.23--7.21 (m, 3H), 6.88 (d, *J* = 8.0 Hz, 2H), 6.82 (d, *J* = 8.0 Hz, 2H), 3.85 (s, 3H), 3.75 (s, 3H), 2.46 (s, 3H), 2.44 (s, 3H); ^13^C NMR (100 MHz, CDCl~3~): δ 190.9, 164.3, 160.0, 159.6, 136.6, 133.0, 132.4, 130.0, 128.2, 126.1, 120.5, 114.3, 113.9, 110.8, 55.5, 55.2, 20.8, 20.7; HRMS (ESI) calcd \[C~27~H~24~N~3~O~3~\] \[M + H\]^+^: 438.1818, found: 438.1809.

#### Phenyl(6-phenylpyrazolo\[1,5-*a*\]pyrimidin-5-yl)methanone (**5a**) {#sec4.2.1.17}

This compound was obtained as a yellow-brown solid (78%) with mp 148.2--149.5 °C; ^1^H NMR (400 MHz, CDCl~3~): δ 8.81 (s, 1H), 8.23 (s, 1H), 7.91 (d, *J* = 8.0 Hz, 2H), 7.58--7.57 (m, 1H), 7.46--7.43 (m, 2H), 7.32 (s, 5H), 6.82 (s, 1H); ^13^C NMR (100 MHz, CDCl~3~): δ 192.6, 155.1, 146.3, 146.1, 135.3, 134.7, 134.4, 134.1, 133.7, 130.4, 129.0, 128.9, 128.7, 128.5, 122.4, 98.1; HRMS (ESI) calcd \[C~19~H~14~N~3~O\] \[M + H\]^+^: 300.1138, found: 300.1131.

#### (3-Methoxyphenyl)(6-(3-methoxyphenyl)pyrazolo\[1,5-*a*\]pyrimidin-5-yl)methanone (**5b**) {#sec4.2.1.18}

This compound was obtained as a yellow solid (72%) with mp 118.1--119.9 °C; ^1^H NMR (400 MHz, CDCl~3~): δ 8.82 (s, 1H), 8.25--8.24 (m, 1H), 7.48--7.43 (m, 2H), 7.36 (t, *J* = 8.0 Hz, 1H), 7.27--7.23 (m, 1H), 7.16--7.13 (s, 1H), 6.91--6.86 (m, 3H), 6.83--6.82 (m, 1H), 3.83 (s, 3H), 3.71 (s, 3H); ^13^C NMR (100 MHz, CDCl~3~): δ 192.5, 159.85, 159.80, 146.4, 146.1, 136.6, 135.0, 134.6, 130.1, 129.7, 123.6, 122.2, 121.3, 121.0, 114.4, 114.3, 113.7, 98.1, 55.5, 55.1; HRMS (ESI) calcd \[C~21~H~18~N~3~O~3~\] \[M + H\]^+^: 360.1349, found: 360.1342.

#### *p*-Tolyl(6-(*p*-tolyl)pyrazolo\[1,5-*a*\]pyrimidin-5-yl)methanone (**5c**) {#sec4.2.1.19}

This compound was obtained as a yellowish solid (75%) with mp 181--183 °C; ^1^H NMR (400 MHz, CDCl~3~): δ 8.51 (s, 1H), 7.96 (s, 1H), 7.88 (d, *J* = 8.0 Hz, 2H), 7.69--7.68 (m, 1H), 7.26--7.24 (m, 2H), 7.20--7.18 (m, 2H), 7.15--7.13 (m, 2H), 2.42 (s, 3H), 2.33 (s, 3H); ^13^C NMR (100 MHz, CDCl~3~): δ 191.8, 155.8, 146.3, 145.1, 138.5, 137.1, 132.9, 132.8, 130.80, 130.78, 129.6, 129.3, 128.7, 123.6, 111.3, 21.8, 21.2; HRMS (ESI) calcd \[C~21~H~18~N~3~O\] \[M + H\]^+^: 328.1451, found: 328.1445.

#### Phenyl(6-phenylimidazo\[1,2-*a*\]pyrimidin-7-yl)methanone (**5d**) {#sec4.2.1.20}

This compound was obtained as a yellowish brown solid (76%) with mp 212.3--213.8 °C; ^1^H NMR (400 MHz, CDCl~3~): δ 8.57 (s, 1H), 7.98--7.94 (m, 3H), 7.71 (s, 1H), 7.60--7.57 (s, 1H), 7.45--7.42 (m, 2H), 7.31--7.29 (m, 5H); ^13^C NMR (100 MHz, CDCl~3~): δ 192.2, 155.1, 146.3, 137.5, 135.4, 134.0, 133.8, 133.3, 130.5, 128.9, 128.6, 128.5, 123.5, 111.6; HRMS (ESI) calcd \[C~19~H~14~N~3~O\] \[M + H\]^+^: 300.1138, found: 300.1129.

#### (3-Methoxyphenyl)(6-(3-methoxyphenyl)imidazo\[1,2-*a*\]pyrimidin-7-yl)methanone (**5e**) {#sec4.2.1.21}

This compound was obtained as a brown solid (74%) with mp 163--166 °C; ^1^H NMR (400 MHz, CDCl~3~): δ 8.59 (s, 1H), 7.98 (s, 1H), 7.72--7.66 (m, 2H), 7.56--7.48 (m, 2H), 7.37--7.34 (m, 1H), 7.27--7.24 (m, 1H), 7.17--7.14 (m, 1H), 6.89--6.86 (s, 2H), 3.84 (s, 3H), 3.71 (s, 3H); ^13^C NMR (100 MHz, CDCl~3~): δ 192.0, 159.8, 155.4, 146.3, 137.4, 133.1, 132.0, 130.0, 129.6, 128.5, 123.9, 121.2, 120.8, 114.5, 114.2, 113.8, 111.6, 55.5, 55.2; HRMS (ESI) calcd \[C~21~H~18~N~3~O~3~\] \[M + H\]^+^: 360.1349, found: 360.1346.

#### *p*-Tolyl(6-(*p*-tolyl)imidazo\[1,2-*a*\]pyrimidin-7-yl)methanone (**5f**) {#sec4.2.1.22}

This compound was obtained as a yellowish solid (79%) with mp 181.2--182.7 °C; ^1^H NMR (400 MHz, CDCl~3~): δ 8.51 (s, 1H), 7.96 (s, 1H), 7.89 (d, *J* = 8.0 Hz, 2H), 7.68 (s, 1H), 7.26--7.24 (m, 2H), 7.20--7.13 (s, 4H), 2.42 (s, 3H), 2.33 (s, 3H); ^13^C NMR (100 MHz, CDCl~3~): δ 191.9, 155.7, 146.4, 145.1, 138.5, 137.3, 133.0, 132.9, 130.86, 130.80, 129.6, 129.3, 128.7, 123.5, 111.3, 21.9, 21.2; HRMS (ESI) calcd \[C~21~H~18~N~3~O\] \[M + H\]^+^: 328.1451, found: 328.1453.

### Procedure for Reduction by Using NaBH~4~ {#sec4.2.2}

A suspension of compound **3a** (1 mmol) in THF/EtOH (4:2 mL) was cooled to 0 °C, and then slow portionwise addition of NaBH~4~ (0.5 mmol) was done. The mixture was stirred at 0 °C for 20 min and at 28 °C for 4 h. The reaction mixture was poured into ice water and extracted with ethyl acetate. The combined organic layers were washed with water twice and finally with saturated brine solution once. The combined organic layers were dried over sodium sulfate and filtered. The volatiles were removed under pressure. The remaining residue was purified by column chromatography on silica gel (*n*-hexane/EtOAc) to yield product **6a**.

#### Phenyl(3-phenylbenzo\[4,5\]imidazo\[1,2-*a*\]pyrimidin-2-yl)methanol (**6a**) {#sec4.2.2.1}

This compound was obtained as a white solid (83%) with mp 189.5--191.3 °C; ^1^H NMR (400 MHz, MeOD): δ 9.86 (s, 1H), 8.84 (d, *J* = 8.0 Hz, 1H), 8.00--7.93 (m, 1H), 7.90 (t, *J* = 8.0 Hz, 1H), 7.74 (t, *J* = 8.0 Hz, 1H), 7.58--7.50 (m, 3H), 7.37--7.34 (s, 2H), 7.24--7.22 (m, 3H), 7.11--7.09 (m, 2H), 6.14 (s, 1H), 3.34--3.32 (m, 1H); ^13^C NMR (100 MHz, CDCl~3~): δ 173.9, 139.7, 136.5, 132.4, 129.8, 129.15, 128.6, 128.1, 128.0, 127.6, 126.9, 125.0, 113.9, 73.4; HRMS (ESI) calcd \[C~23~H~18~N~3~O\] \[M + H\]^+^: 352.1451, found: 352.1441.
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